<?xml version="1.0" encoding="UTF-8"?>
<ref id="B146-pharmaceutics-12-00688">
 <label>146.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kuronuma</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Mitsuzawa</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Takeda</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Nishitani</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>E.D.</given-names>
   </name>
   <name>
    <surname>Kuroki</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Nakamura</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Voelker</surname>
    <given-names>D.R.</given-names>
   </name>
  </person-group>
  <article-title>Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2</article-title>
  <source>J. Biol. Chem.</source>
  <year>2009</year>
  <volume>284</volume>
  <fpage>25488</fpage>
  <lpage>25500</lpage>
  <pub-id pub-id-type="doi">10.1074/jbc.M109.040832</pub-id>
  <pub-id pub-id-type="pmid">19584052</pub-id>
 </element-citation>
</ref>
